The updated five-year overall survival and long-term oxaliplatin-related neurotoxicity assessment of the FACOS study-Reference-Cited by-同舟云学术

The updated five-year overall survival and long-term oxaliplatin-related neurotoxicity assessment of the FACOS study

Published:2021-02-14 Issue:8 Volume:51 Page:1309-1319
ISSN:0941-1291
Container-title:Surgery Today
language:en
Short-container-title:Surg Today

Author:

Takeshita Emiko,Ishibashi Keiichiro,Koda Keiji,Oda Noritaka,Yoshimatsu Kazuhiko,Sato Yu,Oya Masatoshi,Yamaguchi Satoru,Nakajima Hideo,Momma Tomoyuki,Maekawa Hiroshi,Tsubaki Masahiro,Yamada Takeshi,Kobayashi Michiya,Tanakaya Kohji,Ishida Hideyuki

Publisher

Springer Science and Business Media LLC

Subject

General Medicine,Surgery

Link

https://link.springer.com/content/pdf/10.1007/s00595-021-02230-8.pdf

Reference39 articles.

1. André T, de GramontVernerey AD, Chibaudel B, Bonnetain F, Tijeras-Raballand A, et al. Adjuvant fluorouracil, leucovorin, and oxaliplatin in stage II to III colon cancer: updated 10-year survival and outcomes according to BRAF mutation and mismatch repair status of the MOSAIC study. J Clin Oncol. 2015;33:4176–87.

2. Kuebler JP, Wieand HS, O’Connell MJ, Smith RE, Colangelo LH, Yothers G, et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol. 2007;25:2198–204.

3. Schmoll HJ, Tabernero J, Maroun J, de BraudPrice FT, Van Cutsem E, et al. Capecitabine plus oxaliplatin compared with fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results of the NO16968 randomized controlled phase III trial. J Clin Oncol. 2015;33:3733–40.

4. Ishibashi K, Kumamoto K, Koda K, Kato H, Nishimura G, Yoshimatsu K, et al. A phase II clinical study of mFOLFOX6/XELOX as adjuvant chemotherapy after curative resection of stage III colon cancer: the FACOS study. Ann Cancer Res Ther. 2016;24:17–22.

5. Yoshimatsu K, Ishibashi K, Koda K, Yokomizo H, Oda N, Oshiro M, et al. A Japanese multicenter phase II study of adjuvant chemotherapy with mFOLFOX6/CAPOX for stage III colon cancer treatment after D2/D3 lymphadenectomy. Surg Today. 2019;49:498–506.

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. RFC2 promotes aerobic glycolysis and progression of colorectal cancer;BMC Gastroenterology;2023-10-11

2. Deciphering resveratrol's role in modulating pathological pain: From molecular mechanisms to clinical relevance;Phytotherapy Research;2023-10-05

3. Resveratrol ameliorates oxaliplatin‑induced neuropathic pain via anti‑inflammatory effects in rats;Experimental and Therapeutic Medicine;2022-07-21

4. Analgesic effects of medicinal plants and phytochemicals on chemotherapy‐induced neuropathic pain through glial modulation;Pharmacology Research & Perspectives;2021-10-22

5. Systematic review of long-term chemotherapy-induced peripheral neuropathy (CIPN) following adjuvant oxaliplatin for colorectal cancer;Supportive Care in Cancer;2021-08-19